MedTrace Logo

The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation

NCT01129245 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-06-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect that Celebrex (a COX-2 inhibitor and non-steroidal anti-inflammatory drug) has on ovulation.

Conditions

  • Ovulation
  • Luteal Development

Interventions

DRUG

Celebrex

400 mg PO daily intermittently based on hormone and ultrasound findings

DRUG

Placebo

Placebo identical to celecoxib

Sponsors & Collaborators

Principal Investigators

  • Alison Edelman, MD, MPH · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01129245 on ClinicalTrials.gov